Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Bullish +60

5 Revealing Analyst Questions From Zimmer Biomet’s Q1 Earnings Call

📈 Zimmer Biomet reported Q1 2026 revenue of $2.09 billion, beating analyst estimates by 0.9% and showing 9.3% year-over-year growth.

💰 Adjusted EPS came in at $2.09 per share, significantly surpassing the consensus estimate of $1.86 by a 12.2% beat.

🚀 Operating margins expanded to 17.9%, up from 15.3% in the prior year's quarter.

🔧 CEO Ivan Tornos highlighted a greater than 20% increase in partial knee sales driven by the Oxford Partial Cementless Knee.

⚠️ Management noted operational disruptions and tempered momentum due to brand rationalization, account losses, and ongoing U.S. sales force transitions.

📉 Full-year Adjusted EPS guidance was raised to $8.48 at the midpoint, representing a 1.2% increase from previous expectations.

🌍 International revenue growth slowed compared to prior periods due to tougher comparisons, distributor consolidation, and order timing issues.

🛠 Analysts are closely monitoring the pace of U.S. sales force transformation, particularly regarding productivity gains and account retention rates.

🤖 The adoption and clinical rollout of the Monogram robotic system remain a key area of focus for future growth and technology platform adoption.

💸 CFO Suky Upadhyay clarified that underlying gross margin performance was stable, though modest lower margins are expected for the full year absent one-time tariff benefits.

❓ Stifel analyst Frederick Wise questioned why guidance wasn't raised more substantially given the strong quarterly results.

🏦 JPMorgan analyst Robert Marcus inquired about the sustainability of gross margins and the impact of one-time items like tariff-related benefits.

💼 TD Cowen's Matthew Blackman sought specifics on productivity improvements resulting from the ongoing sales force restructuring.

📉 Goldman Sachs' David Roman questioned the slower international growth rate, which management attributes to external distribution changes.

📉 Zimmer Biomet shares traded down from $92.59 to $82.40 following the earnings report despite the positive financial results.

👀 StockStory analysts plan to watch for stabilization in international operations and progress on new technology platforms in upcoming quarters.

📊 The article notes that management remains cautious about full-year potential due to the transitional nature of the current year.

Bullish Signals
  • Zimmer Biomet's first quarter of 2026 revenue reached $2.09 billion, beating Wall Street estimates of $2.07 billion with a year-on-year growth of 9.3%.
  • The company reported an impressive Adjusted EPS beat of 12.2%, reaching $2.09 against the expected $1.86.
  • Zimmer Biomet significantly outperformed on Adjusted EBITDA, recording $840.5 million versus analyst expectations of $633 million, with a 40.3% margin.
  • Management raised its full-year Adjusted EPS guidance to $8.48 at the midpoint, representing a proactive 1.2% increase.
  • Operating margins expanded to 17.9%, up from 15.3% in the same quarter last year, demonstrating improved operational efficiency.
  • Constant Currency Revenue grew 6.8% year-over-year, showing underlying business strength that was not present in the prior period's 2.3% growth.
  • Partial knee sales increased by greater than 20%, driven specifically by strong performance from the Oxford Partial Cementless Knee product line.
Risk Factors
  • Despite beating earnings expectations, Zimmer Biomet's stock price fell significantly to $82.40 from $92.59 just before the report, indicating market skepticism about sustainability.
  • Management explicitly cited ongoing sales force and market changes as reasons for 'prudence' in guidance, leading them to not raise full-year Adjusted EPS guidance more substantially despite a strong quarter.
  • CFO Suky Upadhyay clarified that while Q1 benefited from a one-time tariff-related boost, the underlying performance faces expectations for 'modestly lower gross margin for the year'.
  • CEO Ivan Tornos acknowledged operational disruptions and 'tempered positive momentum' caused by brand rationalization and account losses during the transformation period.
  • International growth remains slower than desired due to distributor consolidation and order timing issues, requiring stabilization before mid-single-digit growth can be realized in the second half.
  • Future performance hinges on critical execution risks including the pace of US sales force transformation impact on productivity and account retention, as well as the adoption of new technology platforms like Monogram robotic system.
Full Analysis
Zimmer Biomet's first quarter of 2026 results surpassed Wall Street expectations for both revenue and non-GAAP earnings, though the market reaction remained negative. The company reported revenue of $2.09 billion, a slight beat over analyst estimates of $2.07 billion and representing 9.3% year-on-year growth, while adjusted EPS hit $2.09 against an estimate of $1.86. Key drivers included a greater than 20% increase in partial knee sales, specifically the Oxford Partial Cementless Knee, alongside robust technology sales and new product launches. However, management acknowledged operational disruptions stemming from ongoing U.S. sales force rationalization and brand account losses, leading CEO Ivan Tornos to characterize the period as one of transition with cautious guidance for the remainder of the year. Despite the strong fundamentals, Wall Street's reaction was mixed due to concerns over near-term headwinds during this transformation phase. The company raised its full-year Adjusted EPS guidance to $8.48 at the midpoint, an increase of 1.2%, while operating margins improved to 17.9% from 15.3% in the prior year. CFO Suky Upadhyay clarified that underlying performance remained stable despite a one-time tariff-related benefit, with expectations for modestly lower gross margins going forward. International growth was described as slower than anticipated due to tough comparisons and distributor consolidation, though mid-single-digit growth is expected in the second half of the year. During the earnings call, analysts focused on several key areas including the pace of the U.S. sales force transition, specifically asking about metrics for non-dedicated reps and account retention. CEO Tornos highlighted rising case counts per representative as a sign of productivity improvement from the transformation but warned that full benefits are still being realized. The company also faces challenges with macro impacts related to Middle East supply chains, though freight cost increases were noted as minor. Investors are now watching closely for stabilization in international operations and the successful adoption of new technology platforms like the Monogram robotic system to ensure Zimmer Biomet meets its long-term growth and margin goals.